Higher birth rate after recombinant hCG triggering compared with urinary-derived hCG in single-blastocyst IVF antagonist cycles: a randomized controlled trial.
In a prospective randomized controlled trial, 119 patients were randomized to receive either recombinant hCG (250 μg) or urinary-derived hCG (10,000 IU) for final oocyte maturation in an antagonist protocol with a fixed dose of recombinant FSH (187.5 IU) and predefined single blastocyst transfer. The delivery rate was improved in the recombinant hCG group compared with the urinary-derived hCG group (44.1 vs. 25.7, respectively); however, adequately powered randomized controlled trials are justified to ascertain whether this difference is true.
Papanikolaou
Evangelos G
EG
Center for Reproductive Medicine, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium. papanikolaou@irg.gr
Fatemi
Human
H
Camus
Michel
M
Kyrou
Dimitra
D
Polyzos
Nikos P
NP
Humaidan
Peter
P
Tarlatzis
Basil
B
Devroey
Paul
P
Tournaye
Herman
H
D000328:Adult; D001723:Birth Rate; D006063:Chorionic Gonadotropin / Q000008:administration & dosage / Q000302:isolation & purification / Q000627:therapeutic use* / Q000652:urine; D004334:Drug Administration Schedule; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage / Q000627:therapeutic use; D005307:Fertilization in Vitro / Q000379:methods*; D006727:Hormone Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007247:Infertility, Female / Q000628:therapy*; D008596:Menotropins / Q000008:administration & dosage / Q000627:therapeutic use*; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D018873:Pregnancy Rate; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D056826:Single Embryo Transfer / Q000379:methods
D006063:Chorionic Gonadotropin; D005300:Fertility Agents, Female; D006727:Hormone Antagonists; D011994:Recombinant Proteins; D008596:Menotropins